{
    "clinical_study": {
        "@rank": "18465", 
        "arm_group": [
            {
                "arm_group_label": "continuous subcutaneous hydrocortisone", 
                "arm_group_type": "Experimental", 
                "description": "continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef \u00ae 50mg/ml infusate"
            }, 
            {
                "arm_group_label": "cortef tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "the patient regular treatment  by  Cortef 5 mg, produced by Nycomed Pharma two times or three times a day."
            }, 
            {
                "arm_group_label": "ultradian subcutaneous hydrocortisone", 
                "arm_group_type": "Experimental", 
                "description": "ultradian subcutaneous hydrocortisone infusion, Solu-Cortef \u00ae 50mg/ml infusate"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to compare the effects of tablet treatment, circadian and combined\n      circadian and ultradian subcutaneous hydrocortisone infusion   on steroid metabolism and\n      tissue responses to therapy."
        }, 
        "brief_title": "Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Addison Disease", 
        "condition_browse": {
            "mesh_term": "Addison Disease"
        }, 
        "detailed_description": {
            "textblock": "The conventional glucocorticoid replacement therapy in primary adrenal insufficiency\n      (Addison's disease) renders the cortisol levels unphysiological, which may cause symptoms\n      and long-term complications. This therapeutical approach does not enable to restore\n      physiological circadian and ultradian rhythm of glucocorticoids. Current studies conclude\n      that constant or unphysiological administration of glucocorticoids leads to abnormal gene\n      transcription and causes sides effect of glucocorticoids treatment and long standing\n      complications Glucocorticoid replacement is technically feasible by continuous subcutaneous\n      hydrocortisone infusion, which can mimic not only the normal diurnal cortisol rhythm, but\n      potentially also the ultradian cadence.\n\n      This is a pilot trial with an open cross-over design of 3 x minimum 2 weeks in 10  patients\n      comparing the effects of tablet treatment versus continuous subcutaneous hydrocortisone\n      infusion versus ultradian subcutaneous hydrocortisone infusion on serum, salivary, tissue\n      hormonal response and glucocorticoid related gene expression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. clinical diagnosis of  primary adrenal insufficiency\n\n          2. Written informed consent\n\n        Exclusion Criteria:.\n\n          1. Diabetes mellitus\n\n          2. Severe cardiovascular disease\n\n          3. Active malignant disease\n\n          4. Pregnancy or breast feeding\n\n          5. treatment with  interfering drugs\n\n          6. Intake of grapefruit juice"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096510", 
            "org_study_id": "2013/1738"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "continuous subcutaneous hydrocortisone", 
                    "cortef tablets", 
                    "ultradian subcutaneous hydrocortisone"
                ], 
                "description": "administration by pump for minimum 2 weeks", 
                "intervention_name": "Solu-Cortef", 
                "intervention_type": "Drug", 
                "other_name": "hydrocortisone"
            }, 
            {
                "arm_group_label": [
                    "continuous subcutaneous hydrocortisone", 
                    "cortef tablets", 
                    "ultradian subcutaneous hydrocortisone"
                ], 
                "description": "tablet treatment 2 ro 3 times per day for 14 days", 
                "intervention_name": "Cortef", 
                "intervention_type": "Drug", 
                "other_name": "hydrocortisone tablets"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Hydrocortisone", 
                "Hydrocortisone-17-butyrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Addison Disease", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "katerina.simunkova@k2.uib.no", 
                "last_name": "Katerina Simunkova, MD, PhD", 
                "phone": "41079948"
            }, 
            "contact_backup": {
                "email": "kristian.lovas@helse-bergen.no", 
                "last_name": "Kristian L\u00f8v\u00e5s, MD, PhD", 
                "phone": "55973075"
            }, 
            "facility": {
                "address": {
                    "city": "Bergen", 
                    "country": "Norway", 
                    "zip": "5021"
                }, 
                "name": "University Hospital Helse Bergen"
            }, 
            "investigator": [
                {
                    "last_name": "Kristian L\u00f8v\u00e5s, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Katerina Simunkova, MD, PhD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "3", 
        "official_title": "Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease", 
        "overall_contact": {
            "email": "kristian.lovas@helse-bergen.no", 
            "last_name": "Kristian L\u00f8v\u00e5s, MD, PhD", 
            "phone": "55973075"
        }, 
        "overall_contact_backup": {
            "email": "katerina.simunkova@k2.uib.no", 
            "last_name": "Katerina Simunkova, MD, PhD", 
            "phone": "41079948"
        }, 
        "overall_official": [
            {
                "affiliation": "Universtity of Bergen", 
                "last_name": "Katerina Simunkova, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Helse Bergen", 
                "last_name": "Kristian L\u00f8v\u00e5s, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Norway: Norwegian Medicines Agency", 
                "Norway: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "admission to hospital for 24 hours", 
            "measure": "Serum cortisol -24 hours curve", 
            "safety_issue": "Yes", 
            "time_frame": "24 hours"
        }, 
        "reference": [
            {
                "PMID": "17609409", 
                "citation": "L\u00f8v\u00e5s K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol. 2007 Jul;157(1):109-12. Erratum in: Eur J Endocrinol. 2008 Jun;158(6):939. Dosage error in article text."
            }, 
            {
                "PMID": "10752074", 
                "citation": "Lightman SL, Windle RJ, Julian MD, Harbuz MS, Shanks N, Wood SA, Kershaw YM, Ingram CD. Significance of pulsatility in the HPA axis. Novartis Found Symp. 2000;227:244-57; discussion 257-60. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096510"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "admission to the hospital for 25 hours", 
                "measure": "Salivary cortisol  - 24 hours curve", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "urine samples for 24 hours", 
                "measure": "24 h urine cortisol and metabolites", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "blood samples", 
                "measure": "levels of corticotropic hormone", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "The tissue effect of glucocorticoid replacement - 24 hours curve of tissue  cortisol (microdialysis)", 
                "measure": "24 hours curve of tissue  cortisol", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "m RNA expression of genes", 
                "measure": "gene expression", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Haukeland University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Haukeland University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}